Please join us for a Takeda-organized symposium during CIIRTA 2025






## Optimizing transition of care in SBS-IF:

Paediatric and adult expert perspectives on GLP-2 analogue therapy

Friday, 12<sup>th</sup> September 2025 | 13:00-13:45 (CEST)
Elite Park Avenue Hotel,
Banquet Hall 1, Gothenburg, Sweden



After the symposium, we are hoping that attendees would have gained better understanding of:

- Early management and PN independence across SBS-IF care pathway
- 2 Treatment advances and MDT care in SBS-IF
- Paediatric to adult
  SBS-IF care transition
  with GLP-2 analogue
- 4 Optimization of current and future SBS-IF care

## **PROGRAMME**

GLP-2 analogue therapy in SBS-IF: Supporting continuity from paediatric to adult care



Dr Lorenzo Norsa (chair) Vittore Buzzi Children's Hospital, University of Milan, Italy



**Prof. Francisca Joly** Hospital Beaujon, Université Paris Cité, France

Followed by interactive audience Q&A and panel discussion

This educational symposium is initiated, organized, and funded by Takeda Pharmaceuticals Company Limited and is intended for healthcare professionals outside of the USA registered for CIIRTA only. This symposium is not affiliated with CIIRTA.

CEST: Central European Summer Time; CIIRTA: Congress of the International Intestinal Rehabilitation and Transplantation Association; GLP-2: glucagon-like peptide 2; MDT: multidisciplinary team; PN: parenteral nutrition; SBS-IF: short bowel syndrome with intestinal failure.

© 2025 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceuticals Company Limited (https://www.takeda.com). Date of preparation: August 2025 | VV-MEDMAT-123551

